ClinicalTrials.gg
Not yet recruitingNCT07313150Updated Dec 31, 2025

A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults

A Phase 1 interventional study of QLS7305 Injection and Placebo Control in Healthy Volunteers - Male and Female, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary characteristics of the investigational drug QLS7305 in healthy adult participants in China. The main questions it aims to answer are:

What is the safety and tolerability profile of single and multiple subcutaneous doses of QLS7305 in healthy adults? What are the pharmacokinetic (PK) characteristics of QLS7305 and its major metabolites? What are the pharmacodynamic (PD) effects of QLS7305 on the complement system (e.g., serum C3 levels and complement activity)? Does QLS7305 induce an immunogenic response (anti-drug antibodies)? What is the effect of QLS7305 on the QTc interval? Investigators will compare different dose levels of QLS7305 to a placebo group to see the effects on safety, tolerability, and the measured parameters.

Participants will:

Be enrolled in one of two parts of the study:

Part A (Single Ascending Dose): Receive a single dose of QLS7305 or placebo. Part B (Multiple Ascending Dose): Receive multiple doses of QLS7305 or placebo (doses selected based on Part A results).

Receive prophylactic antibiotics (Penicillin V) after the first dose until their serum complement C3 level recovers, as a safety precaution.

Undergo close safety monitoring throughout the study, including a follow-up period of up to 337 days to ensure safety parameters return to acceptable levels.

Read the detailed description

The primary objective of this study is to evaluate the safety and tolerability of QLS7305 Injection subcutaneously administered to healthy adults. The secondary objectives are to evaluate the pharmacokinetic (PK) characteristics, the pharmacodynamic (PD) characteristics, the immunogenicity and the effect of subcutaneous injection of QLS7305 injection on QTc interval in healthy adult participants.

This study consists of two parts:

  • Part A (SAD): This part employs a randomized, double-blind, placebo-controlled design. It is planned to include 5 sequential dose groups (50 mg, 100 mg, 200 mg, 400 mg, and 800 mg). A total of 36 participants are planned: 4 participants in the first dose group and 8 participants in each subsequent dose group. Within each dose group, participants will be randomized in a 3:1 ratio to receive a single dose of either QLS7305 or placebo. Dose escalation between dose groups will proceed sequentially based on the review of safety, tolerability, and PK/PD data by the SMC. The SMC may adjust the dose levels and decide on the enrollment strategy for the highest cohort (e.g., staggered enrollment) based on participant safety. The study may be terminated early if a dose is deemed intolerable or if the study objectives are met.
  • Part B (MAD): This part will also use a randomized, double-blind, placebo-controlled design. It is planned to include 2 to 3 dose groups, with 8 participants in each dose group randomized 3:1 to receive QLS7305 or placebo. The specific dose levels and dosing regimen (e.g., on Day 1 and Day 29) for Part B will be determined by the SMC based on the cumulative data from Part A.

Participants will be screened from Day -77 to Day -2. After providing informed consent, participants will receive vaccinations against Neisseria meningitidis and Streptococcus pneumoniae at least two weeks prior to dosing. Eligible participants will be admitted to the clinic on Day -1 for baseline assessments. Dosing will occur on Day 1 (for both parts) and additionally on Day 29 (for Part B). Intensive safety and PK assessments will be performed. Participants will receive prophylactic antibiotic treatment (e.g., Penicillin V) post-dose, which may be discontinued based on the investigator's assessment of serum complement C3 levels and safety risk.

A long-term follow-up period of up to Day 337 post-dose is planned to monitor safety, PD markers (C3, CP, AP), and immunogenicity. Participants with suppressed complement levels at Day 169 will undergo additional follow-up every 8 weeks until recovery (or until Day 337). After Day 337, the unblinded physician may arrange for further monitoring of specific participants if complement levels remain below predefined recovery thresholds.

02

Conditions studied

  • Healthy Volunteers - Male and Female

Keywords

  • QLS7305
  • Double-stranded small interfering ribonucleic acid (siRNA) targeting complement
  • First-in-human
  • C3
  • SAD
  • MAD
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aged between 18 and 55 years (inclusive) Physical examination, vital signs, laboratory tests, 12-lead , and imaging findings are within normal ranges.

Body weight ≥50 kg for males and ≥45 kg for females, with a BM) between 18.0 and 28 kg/m² (inclusive).

Willing or has complied with the administration of meningococcal and pneumococcal vaccines as required by the protocol.

No plan to donate sperm or ova, no pregnancy plan, and voluntarily agrees to use effective methods from the signing of the ICF until 12 months after administration of the product.

Able to understand and comply with the study procedures, voluntarily participate in the trial, and provide written .

Exclusion criteria

Exclusion Criteria:

History of food or drug allergy, and/or known allergy to GalNAc. History of definite infection with encapsulated bacteria within 6 months prior to screening.

History of recurrent or chronic infection within 3 months prior to screening. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection within 1 month prior to baseline.

Any disease at screening that, in the investigator's judgment, could affect the study data.

History of . Any condition that may affect drug absorption. History of splenectomy or congenital asplenia. History of congenital or acquired complement deficiency or disorder. History of allergic diseases (e.g., allergic asthma, allergic rhinitis).

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    QLS7305

    QLS7305 Injection

    Drug: QLS7305 Injection

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo Control

Interventions

  • DrugQLS7305 Injection

    QLS7305 Injection

    Also known as: QLS7305

  • DrugPlacebo Control

    The placebo is a sterile solution that matches the appearance, volume, and packaging of the QLS7305 injection. It contains no active pharmaceutical ingredient and is administered subcutaneously following the same dosing schedule as the active comparator (single or multiple doses).

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Incidence and severity of TEAEs

    Time frame: 337 days

Secondary outcomes

  1. Plasma and urine concentrations of QLS7305

    Time frame: 337 days

  2. Relationship between plasma concentration of QLS7305 and the change in QTc interval.

    Time frame: D3

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data that underlie the results reported in the primary publication (for the primary and secondary endpoints).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 12 months after the primary publication and ending 5 years after the end of the study.

Access criteria: Individual participant data that underlie the results reported in this publication, after de-identification (text, tables, figures, and appendices) will be available. Proposals should be directed to jing16.wang@qilu-pharma.com. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Dec 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Dec 31, 2025
StartEst.
Jan 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07313150
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Jan 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Wu Cuiyun, Professor
Contact
wucuiyun@fudan.edu.cn
021-5288 8921
Zhang Jing, Professor
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion